BioMarin Pharmaceutical, BMRN and Growth Stock

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company reported impressive fourth-quarter results, exceeding analysts' sales and EPS estimates.
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.
Cantor Fitzgerald Reiterates “Overweight” Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a research note issued on Thursday,Benzinga reports.
Scotiabank Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)
In a report released today, George Farmer from Scotiabank maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), with a
Why BioMarin Pharmaceutical Inc. (BMRN) Is Among the Best Healthcare Stocks To Buy According to Analysts
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against the other healthcare stocks.
Zacks.com on MSN4h
Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 40.5% in BioMarin (BMRN). While the effectiveness of this highly sought-after metric is questionable, the ...
Oppenheimer upgrades BioMarin with stage set for increasing interest
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $113.00
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...
Nasdaq3d
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today
BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's ...
BioMarin upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target Discover the Best Stocks and Maximize Your Portfolio: ...
Hosted on MSN4d
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View
BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...
What is Zacks Research’s Estimate for BMRN Q3 Earnings?
Zacks Research raised their Q3 2025 earnings estimates for BioMarin Pharmaceutical in a report released on Monday, February ...
Biomarin Pharmaceutical Inc (BMRN) Q4 2024 Earnings Call Highlights: Record Growth and ...
Biomarin Pharmaceutical Inc (BMRN) reports an 18% revenue increase and significant margin expansion, with promising pipeline developments and strategic market positioning.